Clinical Trial

Pancreatic Cancer Screening in a Population at High Risk

Study acronym: ScrePan
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 21, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Pancreatic cancer is one of the diseases with the worst prognosis, which is mainly due to the initial asymptomatic prognosis. Unfortunately, the incidence of this disease in the Czech Republic is still increasing. In a certain proportion of patients, it is possible to predict the disease, e.g. due to family burdens. Regular follow-up of such individuals is the subject of the SCREPAN study: "Pancreatic Cancer Screening in High-Risk Persons".
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-03-19; most recent amendment 2026-04-16.
Trial Details
NCT Number NCT06330441
Lead Sponsor Masaryk Memorial Cancer Institute
Collaborators: Masaryk University
Conditions Pancreatic Ductal Adenocarcinoma, Hereditary Diseases, Pancreatitis, Chronic
Enrollment 700 participants
Start Date 2022-01-07
Primary Completion 2026-06-30 (estimated)
Study Completion 2028-01-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-21